🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Glofitamab approved in Europe for r/r DLBCL. The CD20×CD3 bispecifics are the most potent single drugs so far tested in this indication, I hope they will be made available #lymsm globenewswire.com/news-release/2…

Central Park geezers

Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy onlinelibrary.wiley.com/doi/10.1111/bj… #lymsm Martin Hutchings Wiley Oncology & Hematology

Excited to present updated results from the Ph1b/2 study of #glofit+pola in r/r LBCL today at #ash2023. ORR in DLBCL 86% incl 63% CR. 73%/57% in HGBCL. Most CRs durable >1y after EOT. #lymsm acrobat.adobe.com/id/urn:aaid:sc…

PhD student Sara Rossetti presents her excellent analysis of the long-term cause-specific mortality in Danish Hodgkin lymphoma patients treated 1995-2015 with contemporary regimens. #ash2023 #lymsm

Great to see our consensus guidelines on CD20x3 #bispecific safety management in a nice PDF @bloodjournal bit.ly/3SvFfhl. Hopefully a useful resource for the roll out of these potent drugs #lymsm #glofitamab #Epcoritamab #mosunetuzumab

Excellent presentation at #eha2024 by Franck Morschhauser of my favourite Phase 1 lymphoma study: The combination of glofitamab and englumafusp alfa in aggressive B-NHL #lymsm

Don't miss Martin Hutchings' presentation on the EORTC-1537 COBRA study on early FDG-PET-response adapted therapy for advanced #HodgkinLymphoma today at #EHA2024. 👉 congress-apps.ehaweb.org/eha2024/en-GB/… European Hematology Association

Managing Hodgkin lymphoma is still a balance between efficacy and toxicity. But we cure more and more patients and with far less severe consequences. I recommend this paper which is the cornerstone of Sara Rossetti's PhD thesis. #lymsm #Hodgkin

Health inequities in the United States keep getting worse. There are 10 Americas as shown below, with stark reduction (widening gaps) of life expectancy thelancet.com/journals/lance… The Lancet Institute for Health Metrics and Evaluation (IHME)

Now that Strava has for some reason decided to destroy one of the best apps available - #fatmap - which are the best alternatives for mountaineering and backcountry skiing?

CONGRESS | #ASH24 | PRESENTATION Martin Hutchings, University of Copenhagen shared extended follow-up data from the phase Ib/II trial of glofitamab + polatuzumab in patients with R/R LBCL including HGBCL. After a median follow-up of 28.2 months, glofitamab + polatuzumab continued to

Hey US, how about you just improve the quality of the cars and food you so desperately want us to buy?

Well thank you so much for the fascist advice, mr VP. Disgusting. nytimes.com/2025/02/14/wor…

Why don't you wear a suit?

CONGRESS | #EHA2025 | PRESENTATION Matthew Ku, University of Melbourne, presented initial findings from a phase Ib trial (NCT05421663) of JNJ-90014496, a CD19/CD20 bispecific CAR-T therapy, in patients with R/R LBCL (N=51). At the RP2D (75M CAR+ T-cells) in 25 evaluable pts, no Grade 3/4 CRS